To include your compound in the COVID-19 Resource Center, submit it here.

AZ's Imfinzi gets Priority Review for NSCLC that has not progressed

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA accepted and granted Priority Review to

Read the full 127 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE